Bruker Corporation
$ 53.41
4.17%
07 Aug - close price
- Market Cap 8,137,511,000 USD
- Current Price $ 53.41
- High / Low $ 53.47 / 51.20
- Stock P/E N/A
- Book Value 15.63
- EPS -0.73
- Next Earning Report -
- Dividend Per Share $0.20
- Dividend Yield 0.39 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.03 %
- 52 Week High 65.30
- 52 Week Low 28.39
About
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Analyst Target Price
$58.75
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-06 | 2026-02-12 | 2025-11-03 | 2025-08-04 | 2025-05-07 | 2025-02-13 | 2024-11-05 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-02 |
| Reported EPS | 0.49 | 0.31 | 0.59 | 0.45 | 0.32 | 0.47 | 0.76 | 0.6 | 0.52 | 0.53 | 0.7 | 0.74 |
| Estimated EPS | 0.38 | 0.23 | 0.65 | 0.32 | 0.42 | 0.44 | 0.74 | 0.6 | 0.51 | 0.46 | 0.66 | 0.63 |
| Surprise | 0.11 | 0.08 | -0.06 | 0.13 | -0.1 | 0.03 | 0.02 | 0 | 0.01 | 0.07 | 0.04 | 0.11 |
| Surprise Percentage | 28.9474% | 34.7826% | -9.2308% | 40.625% | -23.8095% | 6.8182% | 2.7027% | 0% | 1.9608% | 15.2174% | 6.0606% | 17.4603% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-07 | 2026-04-07 | 2026-01-02 | 2025-10-03 | 2025-06-27 | 2025-03-28 | 2024-12-16 | 2024-09-16 | 2024-06-17 | 2024-03-15 |
| Amount | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BRKR
2026-08-08 02:09:41
J.P. Morgan has reiterated its "Buy" rating on Bruker Corp (BRKR.US) but has lowered the price target for the stock to $60. This adjustment reflects a revised outlook from the analyst firm while maintaining a positive investment stance on the company.
2026-08-07 07:09:33
Amundi increased its stake in Bruker Corporation (NASDAQ:BRKR) by 244.2% in the first quarter, now holding 62,611 shares valued at $2.26 million. Despite the company beating EPS estimates for Q2 2026 with $0.49 per share, its revenue of $838.5 million missed analyst expectations, raising concerns about demand and growth in its primary market. Analysts maintain a "Moderate Buy" consensus rating with a target price of $56.64, though some have lowered their targets due to revenue performance.
2026-08-06 14:40:55
FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Bruker Corp (BRKR) common stock, as detailed in a Schedule 13G/A SEC filing. FMR LLC beneficially owns 23,296,465.55 shares, with sole voting power over 17,974,598.38 shares and sole dispositive power over all its shares. Abigail P. Johnson is also listed with beneficial ownership of 23,296,465.55 shares, holding sole dispositive power.
2026-08-06 02:47:37
Bruker Corp (BRKR) shares rose 4.3% to $52.47, trading below its GF Value™ of $62.94, suggesting it is undervalued despite being currently unprofitable and cash-flow negative. The company has a strong GF Score™ of 85/100, driven by good profitability and momentum, though its financial strength is moderate. While gurus are largely increasing their positions, insider selling raises some cautious signals for investors.
2026-08-06 00:40:55
Citi has reiterated its Hold rating on Bruker Corp (BRKR.US) while simultaneously lowering its target price for the company's stock to $53. This adjustment reflects Citi's updated outlook for Bruker Corp.
2026-08-05 20:47:37
Bruker Corp reported its Q2 2026 results, showing a revenue increase to $838.5M from $797.4M a year prior. Despite this growth, the company recorded a net loss of $(62.9)M and diluted EPS of $(0.41), down from a net income of $7.6M and EPS of $0.05 in the year-ago quarter. Revenue growth was driven by demand in biotech, pharma, clinical, and semiconductor markets, though Asia Pacific saw a decline, and the company noted goodwill impairments and restructuring charges impacting its bottom line.
